Regeneron Pharmaceuticals Inc
REGN759.180USD
+4.160+0.55%
종가 02/03, 16:00（ET）시세는 15분 지연됩니다
79.79B시가총액
17.63P/E TTM
자세한 내용은 Regeneron Pharmaceuticals Inc 회사
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Regeneron Pharmaceuticals Inc 정보
종목 코드 REGN
회사 이름Regeneron Pharmaceuticals Inc
상장일Apr 02, 1991
CEOSchleifer (Leonard S)
직원 수15106
유형Ordinary Share
회계 연도 종료Apr 02
주소777 Old Saw Mill River Road
도시TARRYTOWN
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호10591
전화17813705000
웹사이트https://www.regeneron.com/
종목 코드 REGN
상장일Apr 02, 1991
CEOSchleifer (Leonard S)
Regeneron Pharmaceuticals Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.13M
+14941.00%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
688.05K
+17578.00%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
52.18K
-2213.00%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
44.85K
+1080.00%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.17K
-743.00%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
33.06K
+155.00%
Mr. Christopher R. Fenimore
Mr. Christopher R. Fenimore
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
21.78K
+2035.00%
Mr. Arthur F. (Art) Ryan
Mr. Arthur F. (Art) Ryan
Independent Director
Independent Director
17.81K
+155.00%
Ms. Marion E. McCourt
Ms. Marion E. McCourt
Executive Vice President - Commercial
Executive Vice President - Commercial
14.49K
+119.00%
Dr. Michael S. Brown, M.D.
Dr. Michael S. Brown, M.D.
Independent Director
Independent Director
12.77K
+155.00%
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. George D. Yancopoulos, M.D., Ph.D
Dr. George D. Yancopoulos, M.D., Ph.D
Co-Chairman of the Board, President, Chief Scientific Officer
Co-Chairman of the Board, President, Chief Scientific Officer
1.13M
+14941.00%
Dr. Leonard S. Schleifer, M.D., Ph.D
Dr. Leonard S. Schleifer, M.D., Ph.D
Co-Chairman of the Board, President, Chief Executive Officer, Founder
Co-Chairman of the Board, President, Chief Executive Officer, Founder
688.05K
+17578.00%
Dr. Andrew J. Murphy, Ph.D.
Dr. Andrew J. Murphy, Ph.D.
Executive Vice President - Research
Executive Vice President - Research
52.18K
-2213.00%
Mr. Joseph J. LaRosa
Mr. Joseph J. LaRosa
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
44.85K
+1080.00%
Mr. Daniel P. Van Plew
Mr. Daniel P. Van Plew
Executive Vice President, General Manager - Industrial Operations and Product Supply
Executive Vice President, General Manager - Industrial Operations and Product Supply
35.17K
-743.00%
Mr. George L. Sing
Mr. George L. Sing
Independent Director
Independent Director
33.06K
+155.00%
수익 분석
통화: USD마지막 업데이트: Tue, Jan 6
통화: USD마지막 업데이트: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
Sanofi
1.62B
43.07%
EYLEA
680.60M
18.13%
EYLEA HD
430.60M
11.47%
Bayer
344.80M
9.18%
Libtayo
219.10M
5.84%
기타
462.20M
12.31%
기업이 아직 관련 데이터를 공개하지 않았습니다.
사업별
지역별
사업별USD
이름
수익
비율
Sanofi
1.62B
43.07%
EYLEA
680.60M
18.13%
EYLEA HD
430.60M
11.47%
Bayer
344.80M
9.18%
Libtayo
219.10M
5.84%
기타
462.20M
12.31%
주식 보유 통계
마지막 업데이트: Sun, Nov 16
마지막 업데이트: Sun, Nov 16
주주
주주 유형
주주
주주
비율
The Vanguard Group, Inc.
8.73%
BlackRock Institutional Trust Company, N.A.
5.29%
State Street Investment Management (US)
4.54%
Dodge & Cox
4.41%
JP Morgan Asset Management
2.85%
기타
74.18%
주주
주주
비율
The Vanguard Group, Inc.
8.73%
BlackRock Institutional Trust Company, N.A.
5.29%
State Street Investment Management (US)
4.54%
Dodge & Cox
4.41%
JP Morgan Asset Management
2.85%
기타
74.18%
주주 유형
주주
비율
Investment Advisor
45.29%
Investment Advisor/Hedge Fund
31.13%
Hedge Fund
5.04%
Pension Fund
2.77%
Research Firm
2.72%
Bank and Trust
2.20%
Individual Investor
2.07%
Sovereign Wealth Fund
1.23%
Insurance Company
0.20%
기타
7.36%
기관 주식 보유
마지막 업데이트: Thu, Jan 1
마지막 업데이트: Thu, Jan 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q4
2674
93.48M
90.51%
-2.18M
2025Q3
2596
94.26M
91.26%
-4.21M
2025Q2
2585
99.72M
95.69%
-2.03M
2025Q1
2621
99.84M
93.97%
-1.42M
2024Q4
2581
100.17M
93.15%
-475.65K
2024Q3
2505
99.81M
90.67%
-1.99M
2024Q2
2479
100.87M
93.10%
+570.24K
2024Q1
2440
99.77M
92.44%
+388.23K
2023Q4
2406
98.50M
91.94%
-617.06K
2023Q3
2358
98.79M
92.52%
-1.71M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
9.00M
8.71%
-376.36K
-4.02%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
5.46M
5.29%
-204.21K
-3.60%
Sep 30, 2025
State Street Investment Management (US)
4.69M
4.54%
-140.78K
-2.91%
Sep 30, 2025
Dodge & Cox
4.55M
4.41%
+724.56K
+18.94%
Sep 30, 2025
JP Morgan Asset Management
2.95M
2.85%
+130.73K
+4.64%
Sep 30, 2025
Geode Capital Management, L.L.C.
2.54M
2.46%
+70.84K
+2.87%
Sep 30, 2025
Invesco Capital Management (QQQ Trust)
2.32M
2.24%
+133.61K
+6.12%
Dec 31, 2025
Putnam Investment Management, L.L.C.
2.15M
2.08%
+117.43K
+5.78%
Sep 30, 2025
Capital World Investors
2.00M
1.93%
+32.35K
+1.65%
Sep 30, 2025
Loomis, Sayles & Company, L.P.
1.98M
1.92%
+38.38K
+1.98%
Sep 30, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Dec 6
마지막 업데이트: Sat, Dec 6
이름
비율
ProShares Ultra Nasdaq Biotechnology
6.6%
Invesco Nasdaq Biotechnology ETF
6.55%
Amplify Weight Loss Drug & Treatment ETF
6.4%
iShares Biotechnology ETF
5.9%
Simplify Health Care ETF
5.54%
VanEck Biotech ETF
5.51%
Invesco Biotechnology & Genome ETF
5.4%
iShares Genomics Immunology and Healthcare ETF
4.97%
First Trust NASDAQ Pharmaceuticals ETF
4.36%
First Trust NYSE Arca Biotechnology Index Fund
3.88%
더 보기
ProShares Ultra Nasdaq Biotechnology
비율6.6%
Invesco Nasdaq Biotechnology ETF
비율6.55%
Amplify Weight Loss Drug & Treatment ETF
비율6.4%
iShares Biotechnology ETF
비율5.9%
Simplify Health Care ETF
비율5.54%
VanEck Biotech ETF
비율5.51%
Invesco Biotechnology & Genome ETF
비율5.4%
iShares Genomics Immunology and Healthcare ETF
비율4.97%
First Trust NASDAQ Pharmaceuticals ETF
비율4.36%
First Trust NYSE Arca Biotechnology Index Fund
비율3.88%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
Jan 30, 2026
REGN.NB Interim Cash Dividend of gross USD 0.94 paid on Mar 05, 2026 going ex on Feb 20, 2026
Feb 20, 2026
Mar 05, 2026
Feb 20, 2026
Feb 04, 2025
REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025
Feb 20, 2025
Mar 20, 2025
Feb 20, 2025
주식 분할
날짜
배당락일
유형
비율
데이터 없음
날짜
배당락일
유형
비율
데이터 없음
